整合代谢组学与质谱成像揭示黄葵胶囊治疗2型糖尿病肾病的作用与机制
本研究采用db/db小鼠模型,结合UPLC-MS/MS代谢组学与大气压基质辅助激光解吸/电离质谱成像,评价黄葵胶囊对2型糖尿病肾病的疗效并探索其机制。黄葵胶囊通过调控SPT、ALDH1A1、AOX、LRAT和DGAT1等关键酶,纠正鞘脂与视黄醇代谢紊乱,改善肾功能、氧化应激、炎症和脂代谢。
要点
- 黄葵胶囊可改善db/db小鼠T2DN的病理特征、肾功能及氧化应激、炎症和脂代谢指标。
- 3-脱氢鞘氨醇、视黄醇酯和9-顺式视黄酸可作为T2DN新型疾病特异性生物标志物。
- 黄葵胶囊通过调控SPT、ALDH1A1、AOX、LRAT和DGAT1纠正鞘脂与视黄醇代谢紊乱。
核心结论
- 黄葵胶囊对2型糖尿病肾病db/db小鼠模型具有显著治疗作用,其机制涉及纠正鞘脂与视黄醇代谢紊乱并调控SPT、ALDH1A1、AOX、LRAT和DGAT1活性。
研究设计与样本
- 采用db/db小鼠模型评价黄葵胶囊对T2DN的疗效,并研究其调控的核心通路以确定肾脏保护机制。
- 运用高通量UPLC-MS/MS和多变量分析血清与肾脏代谢谱,鉴定T2DN潜在核心生物标志物。
- 采用大气压基质辅助激光解吸/电离质谱成像定位核心生物标志物与药物活性成分在肾脏组织的原位空间分布。
- 结合生化指标、组织病理学、免疫组化、免疫荧光、分子对接和Western blotting揭示疗效、通路与靶点。
主要发现
- 黄葵胶囊显著改善T2DN的病理特征、肾功能、氧化应激、炎症和脂代谢指标。
- 3-脱氢鞘氨醇、视黄醇酯和9-顺式视黄酸可作为T2DN新型疾病特异性生物标志物。
- 基于新发现的生物标志物,发现槲皮素、杨梅素和异鼠李素作用于视黄醇与鞘脂代谢通路中的关键酶SPT、ALDH1A1、AOX、LRAT和DGAT1。
- Western blotting显示黄葵胶囊通过靶向这些酶、上调9cRA和视黄醇酯、下调3-脱氢鞘氨醇、增加TGF-β信号转导、抑制免疫纤维化蛋白OX-8、Col-I和α-SMA表达、抑制Th17细胞发育和神经酰胺合成、降低IL-1β、TNF-α、MDA、TC、LDL-C和TG水平并增加SOD活性来改善T2DN。
临床怎么用
- 黄葵胶囊可作为T2DN的潜在治疗选择,其作用与纠正鞘脂和视黄醇代谢紊乱相关。
- 3-脱氢鞘氨醇、视黄醇酯和9-顺式视黄酸等生物标志物可能有助于T2DN的疾病监测与机制研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Huangkui capsule (HKC), a Chinese patent medicine, is clinically used for treating diabetic nephropathy. However, the core disease-specific biomarkers and targets of type 2 diabetic nephropathy (T2DN) and the therapeutic mechanism of HKC are not fully elucidated. PURPOSE: This study aimed to investigate the therapeutic effects and underlying molecular mechanisms of HKC for T2DN. STUDY DESIGN: The db/db mouse model was used to evaluate the efficacy of HKC for T2DN, and the core pathways regulated by HKC were studied to determine its kidney protective mechanism. METHODS: High-throughput UPLC-MS/MS and multivariate analysis were employed to analyze the serum and kidney metabolic profiles of db/db mice, identifying potential core biomarkers of T2DN. Atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry imaging was used to locate in situ spatial distribution of core biomarkers and drug active ingredients in kidney tissues. Biochemical indicators, histopathology, immunohistochemistry, immunofluorescence, molecular docking, and western blotting were combined to reveal therapeutic effects, pathways, and targets of HKC. RESULTS: HKC substantially improved pathological characteristics, kidney function, oxidative stress, inflammation, and lipid metabolism indicators of T2DN. Twelve core disease-specific biomarker that significantly influenced clustering were identified and its unique spatial distribution information in the kidneys was revealed. 3-dehydrosphinganine, retinyl ester, and 9-cis-retinoic acid (9cRA) could serve as novel disease-specific biomarkers for T2DN. Based on newly discovered biomarkers, quercetin, myricetin, and isorhamnetin were found to act on key enzymes SPT, ALDH1A1, AOX, LRAT, and DGAT1 in retinol and sphingolipid metabolism pathways. Western blotting showed that HKC ameliorated T2DN by targeting these enzymes, upregulating 9cRA and retinyl ester, downregulating 3-dehydrosphinganine, increasing TGF-β signal transduction, inhibiting the expression of the immune fibrosis proteins OX-8, Col-I and α-SMA, inhibiting Th17 cell development and ceramide synthesis, reducing IL-1β, TNF-α, MDA, TC, LDL-C, and TG levels, and increaseing SOD activity. CONCLUSIONS: HKC exerts significant therapeutic effects on T2DN. HKC corrects the metabolic disorder of sphingolipids and retinol, and improves T2DN by regulating the activities of SPT, ALDH1A1, AOX, LRAT, and DGAT1. This study provides valuable ideas and new mechanistic insights for the treatment of T2DN with HKC.
引用
- Han J, Li P, Sun H, et al. Integrated metabolomics and mass spectrometry imaging analysis reveal the efficacy and mechanism of Huangkui capsule on type 2 diabetic nephropathy. Phytomedicine. 2025. PMID: 39862790. doi:10.1016/j.phymed.2025.156397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。